Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many pharmaceutical companies have promised to build.

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to ...